Hydrogen Therapy Shows Promise for COPD in Elderly Patients
- Authors
- Ya-Ting Chuang, Chun Tseng, Tao-An Chen
- Journal
- Open Medicine
- Year
- 2026
- DOI
- 10.1515/med-2026-1438
- Study Type
- clinical
- Peer Reviewed
- Yes
- Country
- Taiwan
- Health Condition
- Chronic Obstructive Pulmonary Disease
- Body System
- Respiratory
TL;DR
Scientists found that breathing in molecular hydrogen gas might help older people with a lung disease called COPD by reducing inflammation and damage in their lungs, which could help them breathe better and exercise more. However, they need to do more studies to make sure it actually works before doctors can use it as a real treatment.
Key Finding
Molecular hydrogen therapy reduced inflammatory markers and oxidative stress indicators while improving blood oxygen levels and exercise tolerance in COPD patients, particularly older adults, across both animal and human studies.
Summary
This review examined whether molecular hydrogen (H2)—a gas with antioxidant and anti-inflammatory properties—might help treat COPD (a lung disease involving chronic inflammation and damage), especially in older adults. The researchers looked at three studies: one in animals, one small human study, and one controlled trial. Across these studies, H2 therapy (given by inhalation or in water) reduced markers of inflammation and oxidative stress (cellular damage) and improved blood oxygen levels and exercise ability in elderly COPD patients.
Practical Takeaway
While these findings suggest H2 therapy may help reduce inflammation and improve oxygen levels in COPD patients, this is a narrative review of only three small studies—not a definitive proof of benefit. Much larger and longer clinical trials are needed before H2 can be recommended as a standard treatment. Anyone with COPD considering H2 therapy should discuss it with their doctor first.
Abstract
Objectives: Molecular hydrogen (H2) exhibits selective antioxidant, anti-inflammatory, and anti-senescence properties that may provide therapeutic benefits for chronic obstructive pulmonary disease (COPD), particularly in aging populations where oxidative stress and chronic inflammation are prominent. Given the increasing burden of aging-related COPD and the emerging biological effects of molecular hydrogen, we hypothesized that H2 therapy may exert beneficial effects by modulating oxidative stress, inflammation, and aging pathways. Methods: Following Ferrari's narrative review framework, PubMed and Ovid MEDLINE were searched through October 2025 for clinical and preclinical studies examining H2 interventions in COPD, chronic bronchitis, or emphysema, with emphasis on elderly populations or aging-related models. Results: Three studies met the inclusion criteria: one animal experiment, one prospective clinical study, and one randomized controlled trial. H2 administration, via inhalation or H2-rich water, significantly reduced inflammatory cytokines (IL-1β, IL-6, TNF-α), oxidative markers (8-OHdG), and senescence indicators (p16, p21, β-gal). Clinical findings demonstrated improved arterial blood gases, acid-base balance, and exercise tolerance in elderly COPD patients. Conclusions: H2 therapy shows consistent antioxidative, anti-inflammatory, and anti-senescence effects across preclinical and clinical settings, suggesting potential as an adjunctive treatment for COPD in aging populations. Further large-scale, long-term trials are warranted to confirm efficacy, optimize dosage, and clarify mechanistic pathways.